Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Piramal Enterprises Limited
  6. News
  7. Summary
    500302   INE140A01024


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Piramal Enterprises : Announces Demerger and Simplification of Corporate Structure, To Create Two Separate Listed Entities in Financial Services and Pharmaceuticals

10/08/2021 | 07:34am EST

Mumbai, India - The Board of Directors of Piramal Enterprises Limited ('PEL', NSE: PEL, BSE: 500302), in their meeting held approved a composite scheme of arrangement providing for the demerger of the pharmaceuticals business from PEL and simplification of the corporate structure to create two industry-focused listed entities in Financial Services and Pharmaceuticals.

Mr. Ajay Piramal, Chairman, Piramal Group, said, 'Over the years, Piramal Enterprises has grown multi-fold with diverse businesses under one listed holding company structure. In line with our stated strategy, the Board has today approved the demerger and simplification of our corporate structure, to create two independent listed entities in Financial Services and Pharmaceuticals, with a leadership position across the business segments they operate in. It will firmly empower both entities to be future-ready and enable them to independently pursue their growth strategies with sharper focus and identity.

Piramal Enterprises Limited will get transformed into a large listed diversified NBFC, focused on retail and wholesale financing, with a consolidated loan book of ~INR 65,000 Crores. Our retail lending platform will be digitally-led, that will serve the financing needs of the under-served customers in the 'Bharat' market. With the recent acquisition of DHFL, the wholly-owned housing finance housing subsidiary has been significantly scaled to become one of the largest HFCs of our country, focused on affordable housing finance.

Piramal Pharma Limited will be a large India-listed pharma company with proven capabilities in Contract Development & Manufacturing, global distribution of complex hospital generics, and a large geographic footprint in the consumer products market in India. PPL's Contract Development and Manufacturing (CDMO) business is one of the top three in India and the 13th largest globally. PPL's Complex Hospital Generics and India Consumer Healthcare businesses are well positioned with differentiated products and business models. Going forward, in line with our philosophy of 'Doing Well and Doing Good', both the listed entities will continue to work towards creating value for all our stakeholders.'

About the Demerger and Simplification of the Corporate Structure:


The pharmaceuticals business will get demerged from Piramal Enterprises Limited and consolidated in Piramal Pharma Limited (PPL). Hemmo Pharma Private Limited (focused on peptide APIs development and manufacturing capabilities) and Convergence Chemical Private Limited (setup for development, manufacturing and selling speciality fluorochemicals), will get amalgamated with PPL to create a consolidated listed Pharma entity.

In consideration of the demerger, PPL shall issue 4 (four) fully paid-up equity shares of PPL of Rs. 10 each to the shareholders of PEL for every 1 (one) fully paid-up equity share in PEL having a face value of Rs. 2 each held by them, in accordance with the Share Entitlement Ratio

Financial Services:

The amalgamation of PHL Fininvest Private Limited with PEL will create a listed Non-banking Financial Services (NBFC) entity. The merged Housing Finance company, (HFC) post DHFL acquisition, will remain a 100% subsidiary of PEL. Through this demerger and simplification of the corporate structure, the shareholders of PEL will directly own shares in both the listed entities, without any cross-holdings and minority stakes.

The composite Scheme of Arrangement is subject to the approval of the shareholders and creditors of the companies, the Reserve Bank of India (RBI), Securities and Exchange Board of India (SEBI), National Stock Exchange of India Ltd. (NSE), Bombay Stock Exchange Ltd (BSE) Limited, Hon'ble National Company Law Tribunal (NCLT) and other regulatory authorities, as applicable.

Piramal Pharma Limited

PPL will be one of the large India listed Pharma companies focused on customer and patient centricity, with presence in the Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and India Consumer Healthcare markets. PPL operates in large, fragmented and growing markets and industry segments with high entry barriers, where it has a strong position.

PPL offers a portfolio of unique services and products through development and end-to-end manufacturing capabilities across 15 global facilities and a distribution network in over 100 countries. * PPL's Contract Development and Manufacturing (CDMO) business, one of the top three in India and the 13th largest globally, provides differentiated CDMO offerings across large, growing categories such as the development and manufacturing of highly potent active pharmaceutical ingredients, antibody drug conjugation, sterile fill/finish with and without containment, potent solid oral drug products, peptide API products and custom peptide synthesis

PPL's Complex Hospital Generics business caters to hospitals, surgical centers, and veterinary centers with a portfolio of inhalation anaesthetics (amongst top 4 globally), intrathecal therapies for spasticity and pain management (US market leader), injectable pain and anaesthetics, injectable anti-infectives and a growing pipeline of more than 30 products. * PPL's Consumer Healthcare business has built a diverse and extensive portfolio of 21 brands across multiple categories and many of its brands such as Saridon, Littles, I-pill, Lacto, etc. feature in the top 100 OTC brands in India. * The JV with Allergan is the market leader in the fast-growing ophthalmology category in India.

Excellent US FDA compliance track record having successfully cleared all 36 USFDA inspections, 243 other regulatory inspections, and 1,261 customer audits, since the beginning of FY12. * PPL has a track-record of building scalable and diversified pharma businesses with world-class talent in attractive markets. Pharma revenue has grown 3.8 times since the Abbott deal at a CAGR of 14% to INR 5,776 Croresin FY 2021, and EBITDA has gone up 13 times at a CAGR of 28% to INR 1,283 Croresin FY 2021, improving the EBITDA margin from 7% in FY2011 to 22% in FY 2021. It successfully closed and integrated nearly 15 M&A transactions over INR 4,000 Crores, since the Abbot deal in 2010. * PPL raised growth equity from the Carlyle Group in October 2020, significantly strengthening the balance sheet that will accelerate its growth plans. Since FY21, PPL has completed three acquisitions.

About Piramal Enterprises Ltd:

Piramal Enterprises Limited (PEL) is one of the large companies in India, with a presence in Financial Services and Pharmaceuticals. PEL's consolidated revenues were US$1.7 Billion in FY 2021, with ~37% of revenues generated from outside India. In Financial Services, the company offers a wide range of financial products and solutions, with a presence across both retail and wholesale financing. Within retail lending, through its multi-product platform, the company offers home loans, loans for small businesses and loans for working capital to customers in affordable housing and mass affluent segments across Tier I, II and III cities. Within wholesale lending, the business provides financing to real estate developers, as well as corporate clients. The company has also formed strategic partnerships with leading financial institutions such as CPPIB, APG and Ivanhoe Cambridge, etc., across various investment platforms. Piramal Alternatives, the fund management business, provides customised financing solutions to high-quality corporates through - 'Piramal Credit Fund', a performing, sector-agnostic credit fund with capital commitment from CDPQ; and 'IndiaRF', a distressed asset investing platform with Bain Capital Credit, which invests in equity and/or debt across non-real estate sectors. PEL also has equity investments in the Shriram Group, a leading financial conglomerate in India.

Piramal Pharma Limited

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network over 100 countries. PPL includes: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business, selling over-the counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovator and generic companies. PCC's complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The Indian Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the Indian consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received growth equity investment from the Carlyle Group.


Mihir Mukherjee

Corporate Communications

E: Mihir.mukherjee@piramal.com


Hitesh Dhaddha

Investor Relations

E: investor.relations@piramal.com

(C) 2021 Electronic News Publishing, source ENP Newswire

01/10PIRAMAL ENTERPRISES : Pharma Ltd. To Invest Minority Stake in Yapan Bio, India-Based CDMO ..
2021Piramal Enterprises Appoints Rupen Jhaveri as Group President
2021PIRAMAL ENTERPRISES : Organisational Announcement – Appointment of Rupen Jhaveri, Gr..
2021Piramal Enterprises Arm Acquires Minority Stake in Yapan Bio for $13 Million
2021PIRAMAL ENTERPRISES : Organisational Announcement – Resignation of Rajesh Laddha, ED..
2021Shriram Capital Limited agreed to acquire Shrilekha Business Consultancy Private Limite..
2021Shriram Transport Finance Company Limited agreed to acquire Shriram City Union Finance ..
2021India central bank sidesteps proposal on corporate ownership of banks
2021Banks, auto stocks drag Indian shares as inflation fears weigh
2021Piramal Enterprises Limited Reports Earnings Results for the Second Quarter and Six Mon..
More news
Sales 2022 144 B 1 920 M 1 920 M
Net income 2022 24 818 M 332 M 332 M
Net Debt 2022 479 B 6 401 M 6 401 M
P/E ratio 2022 22,4x
Yield 2022 1,35%
Capitalization 563 B 7 529 M 7 527 M
EV / Sales 2022 7,25x
EV / Sales 2023 6,02x
Nbr of Employees 6 638
Free-Float -
Duration : Period :
Piramal Enterprises Limited Technical Analysis Chart | 500302 | INE140A01024 | MarketScreener
Technical analysis trends PIRAMAL ENTERPRISES LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 7
Last Close Price 2 358,25 INR
Average target price 3 120,43 INR
Spread / Average Target 32,3%
EPS Revisions
Managers and Directors
Peter D. DeYoung Chief Executive Officer
Bector Vikram Co-President & Chief Human Resources Officer
Vivek Valsaraj Co-President & Chief Financial Officer
Rupen Jhaveri President
Rajesh Ratanlal Laddha Group Chief Financial Officer & Executive Director
Sector and Competitors